SEC For	m 4 F ORN	14	U	INITE	D STA	ΓES	SE	CUI		SAN			NGE C	OMN	/ISS	SION	1			
Section 16. Form 4 or Form 5 obligations may continue. See						d pursi	T OF CHANGES IN BENEFICIAL OWNER pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										Estir	OMB APPROVA OMB Number: 323 Estimated average burden hours per response:		3235-0287
1. Name and Address of Reporting Person* Lowinger Timothy B																k all appli Directo	cable)		rson(s) to Is 10% O Other (
(Last) (First) (Middle) C/O MERSANA THERAPEUTICS, INC. 840 MEMORIAL DRIVE						3. Date of Earliest Transaction (Month/Day/Year) 09/21/2020									X Oncer (give fue only below) Chief Science, Tech. Officer					
(Street) CAMBRIDGE MA 02139					_ 4.1	Line) X F									Form 1 Form 1	dual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)		(State)		(Zip)						<u> </u>										
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day)					tion	on 2A. Deemed Execution Date,			3. Transaction Code (Instr. 8)			es Acquired	d (A) or	-	5. Amount o		Forr (D) (wnership n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
										Code	v	Amount	(A) or (D)	Price		Transac (Instr. 3	ction(s)			(1150.4)
Common Stock 09				09/21/	/2020				M ⁽¹⁾		3,749	Α	\$3.51		16	16,160		D		
Common Stock 09/21/2					2020				S ⁽²⁾		3,749	D	\$20.6574		12,411			D		
Common Stock 09/21/2					2020				M ⁽¹⁾		4,454	Α	\$6.16		16,865			D		
Common Stock 09/21/					2020	020			S ⁽²⁾		4,454	D	\$20.6574		4 12,411			D		
Common Stock 09/21/20					2020)20			S ⁽²⁾		12,411	11 D \$20		6574	574 0			D		
			т	able II								posed of converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	on Date se (Mont	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr 8)		5. Number on of		6. Date Exerci Expiration Da (Month/Day/Ye		isable and te	7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Di Si (li	Price of erivative ecurity nstr. 5)	9. Numb derivati Securiti Benefici Owned Followir Reporte Transac (Instr. 4)	ve ies ially ng ed ction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficia Ownershi (Instr. 4)
						Code	v	(A) (D)		Date Exercisa	able	Expiration Date	Title	Amou or Numb of Share	nber					
Stock Option (right to buy)	\$3.51	09)/21/2020	Ν		M ⁽¹⁾		3,749		(3)		01/23/2029	Common Stock	¹ 3,749		\$ 0	38,426		D	

Explanation of Responses:

\$<u>6.16</u>

Stock Option (right to buy)

1. The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2020.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 12, 2020.

M⁽¹⁾

3. The options vest in equal quarterly installments over the first four years after the vesting commencement date, January 23, 2019.

4. The options vest in equal quarterly installments over the first four years after the vesting commencement date, January 15, 2020.

/s/ Eva Jack, as Attorney-in-Fact

4,454

\$<mark>0</mark>

Common Stock

01/15/2030

09/23/2020

115,043

D

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

09/21/2020

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

4,454

(4)